RS51007B - Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga - Google Patents
Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz togaInfo
- Publication number
- RS51007B RS51007B RSP-2009/0523A RSP20090523A RS51007B RS 51007 B RS51007 B RS 51007B RS P20090523 A RSP20090523 A RS P20090523A RS 51007 B RS51007 B RS 51007B
- Authority
- RS
- Serbia
- Prior art keywords
- alkoxy
- modulators
- metabolism
- treatment
- pyrimidinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Kompozicija, naznačena time, što se sastoji od:(a)inhibitora dipeptidil peptidaze IV (DPP-IV); i (b)jedinjenja odabranog od jedinjenja formule (la) i njihove farmaceutski prihvatljive soli, solvata i hidrata:pri čemu su:X je N ili CR8 pri čemu je R8 H ili halogen; Y je NH ili O; Z je CH ili N; ,R1 je karbo-C1-6-alkoksi, oksadiazolil ili pirimidinil gde su navedeni karbo-C1-6-alkoksi, oksadiazolil ili pirimidinil svaki opciono supstituisani sa 1 ili 2 supstituentima nezavisno odabranim od: C1-4 alkil, C1-4 alkoksi i C3-5 cikloalkil; R2 je H ili C1-4 alkil;R3 je C1-4 alkoksi, O-C2-4-alkinil ili hidroksil;R4 je odabran od: H, C1-4 alkoksi, C1-4 alkil, C2-4 alkinil i halogen;bilo da:R5 je odabran od:C1-4 acilsulfonamid, C1-4alkoksi, C1-4alkil, C1-4alkilamino, C1-4alkilsulfonil, C1-4alkiltio, cijano, heterociklil, di-C1-4-dialkilamino i silfonamid,pri čemu su navedeni C1-4alkoksi, C1-4alkil, C1-4alkilamino, C1-4alkilsulfonil, C1-4alkiltio, di-C1-4-dialkilamino i heterociklil svaki opciono supstituisani sa 1 ili 2 supstituenata nezavisno odabranih od:C2-4alkinil, C1-4alkoksi, C1-4alkilkarboksamid, C1-4alkilsulfonil, C3-5cikloalkil, C3-5cikloalkiloksi, di-C1-4-alkilkaboksamid, hidroksil i fosfonooksi,pri čemu je navedeni C1-4alkilkarboksamid opciono supstituisan sa hidroksil; iliR5 je grupa Formule (A):pri čemu su:"m", "n" i "q" svaki nezavisno 0, 1, 2 ili 3; "r"je 0, 1 ili 2; i T je 0 ili 1;R6 je H ili halogen; i R7 je H ili C1-4alkil.Prijava sadrži još 61 patentni zahtev.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64284005P | 2005-01-10 | 2005-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS51007B true RS51007B (sr) | 2010-10-31 |
Family
ID=36755755
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2009/0523A RS51007B (sr) | 2005-01-10 | 2006-01-09 | Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga |
| RSP-2008/0068A RS50540B (sr) | 2005-01-10 | 2006-01-09 | Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2008/0068A RS50540B (sr) | 2005-01-10 | 2006-01-09 | Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US20060155128A1 (sr) |
| EP (2) | EP1732562B1 (sr) |
| JP (1) | JP2008526882A (sr) |
| KR (1) | KR20070098907A (sr) |
| CN (2) | CN102125555A (sr) |
| AR (1) | AR054320A1 (sr) |
| AT (2) | ATE381558T1 (sr) |
| AU (1) | AU2006211583C1 (sr) |
| BR (1) | BRPI0606704A (sr) |
| CA (1) | CA2594466A1 (sr) |
| CR (1) | CR9225A (sr) |
| CY (2) | CY1107215T1 (sr) |
| DE (2) | DE602006000339T2 (sr) |
| DK (2) | DK1911756T3 (sr) |
| EA (1) | EA015714B1 (sr) |
| ES (2) | ES2333824T4 (sr) |
| GE (1) | GEP20094828B (sr) |
| GT (1) | GT200600006A (sr) |
| HK (2) | HK1094542A1 (sr) |
| HN (2) | HN2006000969A (sr) |
| HR (2) | HRP20080113T3 (sr) |
| IL (1) | IL184363A0 (sr) |
| MX (1) | MX2007008402A (sr) |
| MY (1) | MY148521A (sr) |
| NI (1) | NI200700169A (sr) |
| NO (1) | NO20073806L (sr) |
| NZ (1) | NZ556220A (sr) |
| PE (2) | PE20091590A1 (sr) |
| PL (2) | PL1911756T3 (sr) |
| PT (2) | PT1911756E (sr) |
| RS (2) | RS51007B (sr) |
| SG (1) | SG158875A1 (sr) |
| SI (2) | SI1732562T1 (sr) |
| TW (1) | TW200637845A (sr) |
| UA (1) | UA89812C2 (sr) |
| WO (1) | WO2006083491A2 (sr) |
| ZA (1) | ZA200705471B (sr) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| CN1751038A (zh) * | 2003-02-24 | 2006-03-22 | 艾尼纳制药公司 | 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗 |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE602005011279D1 (de) * | 2004-06-04 | 2009-01-08 | Arena Pharm Inc | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| US20090099200A1 (en) * | 2005-06-09 | 2009-04-16 | Chun Sing Li | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AU2006259137B2 (en) * | 2005-06-14 | 2010-04-01 | F. Hoffmann-La Roche Ag | Anthranilic acid derivatives |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| CN101263135A (zh) * | 2005-09-16 | 2008-09-10 | 艾尼纳制药公司 | 代谢调节剂和代谢相关病症的治疗 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP1971862B1 (en) | 2006-04-11 | 2010-11-10 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| CA2810522A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
| TW200811147A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| TW200811140A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| PE20090213A1 (es) * | 2007-05-04 | 2009-02-28 | Bristol Myers Squibb Co | Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos |
| PE20090222A1 (es) * | 2007-05-04 | 2009-03-27 | Bristol Myers Squibb Co | Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119 |
| US8003796B2 (en) * | 2007-07-17 | 2011-08-23 | Bristol-Myers Squibb Company | Pyridone GPR119 G protein-coupled receptor agonists |
| AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ES2499018T3 (es) * | 2007-09-20 | 2014-09-26 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de GPR119 |
| NZ585284A (en) * | 2007-10-16 | 2011-03-31 | Daiichi Sankyo Co Ltd | Pyrimidyl indoline compounds with hypoglycaemic effect useful in the treatment of diabetes related diseases and adiposity |
| JP2011500727A (ja) * | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 |
| CN102036561A (zh) * | 2008-02-29 | 2011-04-27 | 赛林药物股份有限公司 | 蛋白激酶调节剂 |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| CA2727174A1 (en) * | 2008-06-20 | 2010-01-21 | Jiangao Song | Aryl gpr119 agonists and uses thereof |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US8513264B2 (en) * | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| WO2010059384A1 (en) * | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| WO2010059385A1 (en) * | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidne derivatives useful as gdir agonists |
| US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| JP2012513469A (ja) * | 2008-12-23 | 2012-06-14 | シェーリング コーポレイション | ピリミジン誘導体及びその使用法 |
| EP2382203B1 (en) | 2008-12-23 | 2015-01-14 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| US8410089B2 (en) | 2009-02-18 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| TW201039827A (en) * | 2009-04-15 | 2010-11-16 | Daiichi Sankyo Co Ltd | Indoline compound |
| WO2010135506A1 (en) * | 2009-05-20 | 2010-11-25 | Janssen Pharmaceutica Nv | Process for the preparation of 4- [6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino) -5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
| US20110015215A1 (en) * | 2009-05-20 | 2011-01-20 | Paul Deghetto | Crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
| EP2445878A1 (en) | 2009-06-24 | 2012-05-02 | Boehringer Ingelheim International GmbH | New compounds, pharmaceutical composition and methods relating thereto |
| AR077214A1 (es) | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
| ES2497566T3 (es) | 2009-10-01 | 2014-09-23 | Cymabay Therapeutics, Inc. | Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida |
| KR102668834B1 (ko) | 2009-11-27 | 2024-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| SG184168A1 (en) | 2010-04-08 | 2012-10-30 | Bristol Myers Squibb Co | Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| CN102971311B (zh) | 2010-05-06 | 2015-07-08 | 百时美施贵宝公司 | 作为gpr119调节剂的二环杂芳基化合物 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| EP2585048B1 (en) | 2010-06-23 | 2018-04-11 | CymaBay Therapeutics, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
| MX2013002430A (es) | 2010-09-01 | 2013-07-22 | Arena Pharm Inc | Formas de dosis de disolucion de rápida de agonistas de 5-ht2c. |
| CN103189359A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的光学活性酸盐 |
| KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태 |
| EP2611433A2 (en) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료 |
| BR112013007904A2 (pt) * | 2010-10-08 | 2019-09-24 | Cadila Healthcare Ltd | "composto, composição farmacêutica, medicamento, uso de um composto e proceso para preparar um composto" |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| CA2818050A1 (en) | 2010-11-26 | 2012-05-31 | Lupin Limited | Bicyclic gpr119 modulators |
| WO2012093809A2 (en) * | 2011-01-03 | 2012-07-12 | Hanmi Pharm Co., Ltd. | New bicyclic compound for modulating g protein-coupled receptors |
| WO2012145603A1 (en) * | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| US9174965B2 (en) | 2012-05-16 | 2015-11-03 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| CN105101829B (zh) * | 2013-03-15 | 2017-11-10 | 耐克创新有限合伙公司 | 包括包含波涛结构的鞋底结构的鞋类物品 |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| MX2017008925A (es) | 2015-01-06 | 2017-10-11 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| PT3310760T (pt) | 2015-06-22 | 2022-11-10 | Arena Pharm Inc | Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1 |
| MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
| CN109862896A (zh) | 2016-08-03 | 2019-06-07 | 西玛贝医药公司 | 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物 |
| CA3039026A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition |
| JP2020507611A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 原発性胆汁性胆管炎の治療のための化合物および方法 |
| JP2020524181A (ja) | 2017-06-19 | 2020-08-13 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｎａｆｌｄおよびｎａｓｈの治療のための化合物および方法 |
| CN108658871B (zh) * | 2018-06-19 | 2020-10-30 | 舞阳威森生物医药有限公司 | 周效磺胺中间体4,6-二氯-5-甲氧基嘧啶的制备方法 |
| CN108892635A (zh) * | 2018-09-07 | 2018-11-27 | 江苏工程职业技术学院 | 一种西沙必利关键中间体的制备方法 |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US427174A (en) * | 1890-05-06 | Minor c | ||
| US618777A (en) * | 1899-01-31 | Window | ||
| CH389134A (de) | 1960-03-15 | 1965-03-15 | Ciba Geigy | Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe |
| CH478817A (de) | 1965-10-22 | 1969-09-30 | Ciba Geigy | Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen |
| CH480410A (de) * | 1967-01-09 | 1969-10-31 | Geigy Ag J R | Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen |
| CA961052A (en) | 1967-01-12 | 1975-01-14 | Max Schellenbaum | N-2-ethylhexyl-n'-aryl ureas and preparation containing them |
| FR1593586A (sr) | 1967-10-17 | 1970-06-01 | ||
| US3608087A (en) | 1968-06-21 | 1971-09-21 | Merck & Co Inc | Feed compositions |
| US3887329A (en) | 1969-05-05 | 1975-06-03 | Ciba Geigy Ag | Hexamethyl phosphotriamide-dye compositions |
| BE756953A (fr) | 1969-10-02 | 1971-04-01 | Merck & Co Inc | Potentialisation d'antibiotiques |
| US3686238A (en) | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
| US3852434A (en) | 1970-09-11 | 1974-12-03 | Merck & Co Inc | Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof |
| US3690834A (en) | 1971-01-11 | 1972-09-12 | Syva Co | Ligand determination with spin labeled compounds by receptor displacement |
| US3966744A (en) | 1971-01-11 | 1976-06-29 | Syva Company | Spin labeled compounds |
| DE2106585A1 (de) | 1971-02-11 | 1972-08-24 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Aminothiodiazole und Thiodiazol-Azofarbstoffe |
| CH558137A (de) | 1971-05-17 | 1975-01-31 | Ciba Geigy Ag | Mittel zur beeinflussung des pflanzenwachstums. |
| CH560197A5 (en) | 1971-05-17 | 1975-03-27 | Ciba Geigy Ag | 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides |
| US3966764A (en) | 1972-07-10 | 1976-06-29 | Syva Company | Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs |
| US3849420A (en) | 1972-10-20 | 1974-11-19 | Dow Chemical Co | Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines |
| CH574206A5 (sr) * | 1972-11-16 | 1976-04-15 | Ciba Geigy Ag | |
| DE2340569C2 (de) | 1973-08-10 | 1982-12-02 | Bayer Ag, 5090 Leverkusen | Azofarbstoffe |
| AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
| DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| CH584739A5 (sr) | 1973-12-21 | 1977-02-15 | Ciba Geigy Ag | |
| US4101541A (en) | 1973-12-21 | 1978-07-18 | Ciba-Geigy Corporation | 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs |
| FR2258841B1 (sr) | 1974-01-29 | 1977-11-04 | Ugine Kuhlmann | |
| AT327605B (de) | 1974-05-06 | 1976-02-10 | Ciba Geigy Ag | Mittel zur hemmung des pflanzenwachstums |
| AU492126B2 (en) | 1974-05-14 | 1975-11-20 | Ciba-Geigy Ag | Nitropyrimidine derivatives |
| FR2306697A1 (fr) | 1975-04-10 | 1976-11-05 | Sogeras | Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants |
| DE2731264A1 (de) | 1977-07-11 | 1979-02-01 | Boehringer Mannheim Gmbh | Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen |
| JPS6038696B2 (ja) | 1977-12-09 | 1985-09-02 | コニカ株式会社 | ハロゲン化銀カラ−写真感光材料 |
| US4242507A (en) | 1978-02-23 | 1980-12-30 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonic acid esters |
| DE2831580C2 (de) * | 1978-07-18 | 1980-09-18 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und Reagens zur Bestimmung von Glycerin |
| DE2831850A1 (de) | 1978-07-20 | 1980-02-07 | Basf Ag | N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel |
| DE2906603A1 (de) | 1979-02-21 | 1980-09-04 | Boehringer Mannheim Gmbh | N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel |
| DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| DE3334455A1 (de) | 1983-03-04 | 1984-09-06 | Bayer Ag, 5090 Leverkusen | Guanidin - derivate |
| ZA848275B (en) | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
| DE3406329A1 (de) | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
| PH22302A (en) | 1985-02-11 | 1988-07-22 | Fujisawa Pharmaceutical Co | Piperidine compounds |
| GR860542B (en) | 1985-03-01 | 1986-06-25 | Duphar Int Res | Benzoyl urea derivatives having antitumor activity |
| DE3601196A1 (de) | 1986-01-17 | 1987-07-23 | Merck Patent Gmbh | 1,4-dihydropyridine |
| CA1340284C (en) | 1987-03-19 | 1998-12-22 | Zeneca Inc. | Herbicidal substituted cyclic diones |
| DE68926687T2 (de) | 1988-01-11 | 1997-03-06 | Fuji Photo Film Co Ltd | Verfahren zur Erzeugung von extrem hochkontrastreichen negativen Bildern |
| CA2070978A1 (en) | 1991-06-11 | 1992-12-12 | William J. Greenlee | Cyclic renin inhibitors |
| EP0556889A1 (en) | 1992-02-18 | 1993-08-25 | Duphar International Research B.V | Method of preparing aryl(homo)piperazines |
| TW237456B (sr) | 1992-04-09 | 1995-01-01 | Ciba Geigy | |
| DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB9400889D0 (en) | 1994-01-18 | 1994-03-16 | Sandoz Ltd | Novel compounds |
| TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| WO1996007641A1 (fr) * | 1994-09-09 | 1996-03-14 | Nippon Shinyaku Co., Ltd. | Derive heterocyclique et medicament |
| RO118426B1 (ro) | 1994-11-29 | 2003-05-30 | Dainippon Pharmaceutical Co | Derivati de indol utilizati pentru tratarea diabetului zaharat si a obezitatii |
| US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US6956047B1 (en) * | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| EP0940387B1 (en) | 1995-10-26 | 2003-05-07 | Mitsubishi Pharma Corporation | Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same |
| US5849759A (en) | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| DE19602095A1 (de) | 1996-01-22 | 1997-07-24 | Bayer Ag | Halogenpyrimidine |
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US6008234A (en) * | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
| NO980546L (no) | 1997-02-11 | 1998-08-12 | Lilly Co Eli | Farmas°ytiske midler |
| DE19737723A1 (de) | 1997-08-14 | 1999-02-18 | Bayer Ag | Methoximinomethyloxadiazine |
| US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
| US6239126B1 (en) * | 1998-12-17 | 2001-05-29 | American Home Products Corporation | Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| WO2000071536A1 (en) * | 1999-05-20 | 2000-11-30 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
| EP1074549B1 (en) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| DE19962936A1 (de) | 1999-12-24 | 2001-06-28 | Bayer Ag | Neue beta-Aminosäureverbindungen als Integrinantagonisten |
| US6569879B2 (en) * | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| PT1287133E (pt) | 2000-05-18 | 2007-03-30 | Bayer Healthcare Ag | Regulação do receptor acoplado à proteína g tipo dopamina humano |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| AU6871801A (en) * | 2000-06-29 | 2002-01-14 | Abbott Lab | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| EP1347755A2 (en) * | 2000-10-31 | 2003-10-01 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| US20020058026A1 (en) * | 2000-11-13 | 2002-05-16 | Milton Hammerly | HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10 |
| CA2429426A1 (en) | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Isoxazole derivatives |
| US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| US6525064B1 (en) * | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6545016B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| CZ305202B6 (cs) * | 2001-01-26 | 2015-06-10 | Merck Sharp & Dohme Corp. | Farmaceutický prostředek |
| WO2003002544A1 (en) * | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
| GB2393825B (en) | 2001-08-02 | 2006-02-15 | Halliburton Energy Serv Inc | Adaptive acoustic transmitter controller apparatus and method |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| US20070225351A1 (en) * | 2002-01-11 | 2007-09-27 | Lippa Arnold S | Methods and compositions for controlling body weight and appetite |
| US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| CA2488498A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International Limited | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| SE0201976D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE60327211D1 (de) | 2002-06-28 | 2009-05-28 | Glykos Finland Oy | Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall |
| US7071210B2 (en) | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US20040053842A1 (en) | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| EP1554256B1 (en) | 2002-07-15 | 2009-12-09 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| ATE400564T1 (de) | 2002-07-30 | 2008-07-15 | Merck & Co Inc | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen |
| EP1539137B1 (en) | 2002-07-30 | 2010-05-26 | Merck Sharp & Dohme Corp. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| EP1717220A3 (en) | 2002-08-08 | 2007-08-22 | Amgen, Inc | Vanilloid receptor ligands and their use in treatments |
| US20060167045A1 (en) | 2002-08-21 | 2006-07-27 | Joanne Waldstreicher | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist |
| RU2328483C2 (ru) | 2002-08-29 | 2008-07-10 | Мерк Энд Ко., Инк. | Индолы, обладающие противодиабетической активностью |
| CA2495915A1 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| WO2004033710A2 (en) | 2002-10-09 | 2004-04-22 | Genaissance Pharmaceuticals, Inc. | Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol |
| EP1558609A4 (en) * | 2002-10-30 | 2008-05-28 | Merck & Co Inc | KINASE INHIBITORS |
| US7098235B2 (en) * | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| US20040110241A1 (en) * | 2002-12-06 | 2004-06-10 | Segal Mark S. | Materials and methods for monitoring vascular endothelial function |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| US7714004B2 (en) | 2002-12-20 | 2010-05-11 | Bayer Pharmaceuticals Corporation | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
| EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| AU2004207444B2 (en) | 2003-01-17 | 2008-07-31 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| CN1751038A (zh) * | 2003-02-24 | 2006-03-22 | 艾尼纳制药公司 | 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗 |
| JP2004269469A (ja) | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| JP2004269468A (ja) | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| CA2520405A1 (en) | 2003-03-28 | 2004-10-07 | Pfizer Products Inc. | 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity |
| TWI494102B (zh) | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| DE60333546D1 (de) | 2003-05-06 | 2010-09-09 | Univ Palackeho | PyrazoloÄ4,3-DÜpyrimidines, verfahren zur ihre herstellung und deren verwendung |
| US7083933B1 (en) * | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| US20060160834A1 (en) | 2003-06-06 | 2006-07-20 | Fong Tung M | Combination therapy for the treatment of hypertension |
| WO2004110375A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| CN102417508A (zh) * | 2003-07-14 | 2012-04-18 | 艾尼纳制药公司 | 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症 |
| FI116461B (fi) * | 2004-03-18 | 2005-11-30 | Kone Corp | Menetelmä hissin asentamiseksi ja hissin toimituskokonaisuus |
| DE602005011279D1 (de) * | 2004-06-04 | 2009-01-08 | Arena Pharm Inc | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen |
| DE602005025924D1 (en) | 2004-09-20 | 2011-02-24 | Xenon Pharmaceuticals Inc | Royl-coa-desaturase |
| JP4797021B2 (ja) | 2004-10-01 | 2011-10-19 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療または予防用のジペプチジルペプチダ−ゼ−ｉｖ阻害剤としてのアミノピペリジン |
| WO2006052566A2 (en) | 2004-11-03 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Gpr41 and modulators thereof for the treatment of insulin-related disorders |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| US20080124384A1 (en) | 2005-01-19 | 2008-05-29 | Blum Charles A | Heteroaryl Substituted Piperazinyl-Pyridine Analogues |
| AU2006265840B2 (en) | 2005-07-01 | 2010-02-11 | Irm Llc | Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors |
| TW200745055A (en) | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| CA2635531C (en) | 2005-12-29 | 2014-06-17 | Lexicon Pharmaceutical Inc. | Multicyclic amino acid derivatives and methods of their use |
| BRPI0621226A2 (pt) * | 2006-01-19 | 2012-07-10 | Orchid Reseach Lab Ltd | compostos heterociclos |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
-
2006
- 2006-01-04 MY MYPI2010006219A patent/MY148521A/en unknown
- 2006-01-06 PE PE2009001073A patent/PE20091590A1/es not_active Application Discontinuation
- 2006-01-06 PE PE2006000046A patent/PE20060857A1/es not_active Application Discontinuation
- 2006-01-09 ES ES07023528T patent/ES2333824T4/es active Active
- 2006-01-09 SI SI200630025T patent/SI1732562T1/sl unknown
- 2006-01-09 MX MX2007008402A patent/MX2007008402A/es active IP Right Grant
- 2006-01-09 PT PT07023528T patent/PT1911756E/pt unknown
- 2006-01-09 HN HN2006000969A patent/HN2006000969A/es unknown
- 2006-01-09 DK DK07023528.8T patent/DK1911756T3/da active
- 2006-01-09 CA CA002594466A patent/CA2594466A1/en not_active Abandoned
- 2006-01-09 WO PCT/US2006/000567 patent/WO2006083491A2/en active Application Filing
- 2006-01-09 RS RSP-2009/0523A patent/RS51007B/sr unknown
- 2006-01-09 SI SI200630527T patent/SI1911756T1/sl unknown
- 2006-01-09 SG SG201000207-9A patent/SG158875A1/en unknown
- 2006-01-09 AU AU2006211583A patent/AU2006211583C1/en not_active Ceased
- 2006-01-09 EA EA200701471A patent/EA015714B1/ru not_active IP Right Cessation
- 2006-01-09 AT AT06733644T patent/ATE381558T1/de active
- 2006-01-09 DE DE602006000339T patent/DE602006000339T2/de active Active
- 2006-01-09 ES ES06733644T patent/ES2299167T4/es active Active
- 2006-01-09 PT PT06733644T patent/PT1732562E/pt unknown
- 2006-01-09 CN CN201010617617XA patent/CN102125555A/zh active Pending
- 2006-01-09 AR ARP060100071A patent/AR054320A1/es not_active Application Discontinuation
- 2006-01-09 BR BRPI0606704-2A patent/BRPI0606704A/pt not_active IP Right Cessation
- 2006-01-09 RS RSP-2008/0068A patent/RS50540B/sr unknown
- 2006-01-09 PL PL07023528T patent/PL1911756T3/pl unknown
- 2006-01-09 JP JP2007550520A patent/JP2008526882A/ja active Pending
- 2006-01-09 DK DK06733644T patent/DK1732562T3/da active
- 2006-01-09 UA UAA200709148A patent/UA89812C2/ru unknown
- 2006-01-09 TW TW095100772A patent/TW200637845A/zh unknown
- 2006-01-09 CN CNA2006800044893A patent/CN101115740A/zh active Pending
- 2006-01-09 PL PL06733644T patent/PL1732562T3/pl unknown
- 2006-01-09 NZ NZ556220A patent/NZ556220A/en not_active IP Right Cessation
- 2006-01-09 DE DE602006009946T patent/DE602006009946D1/de active Active
- 2006-01-09 EP EP06733644A patent/EP1732562B1/en active Active
- 2006-01-09 AT AT07023528T patent/ATE446293T1/de active
- 2006-01-09 GT GT200600006A patent/GT200600006A/es unknown
- 2006-01-09 KR KR1020077018314A patent/KR20070098907A/ko not_active Application Discontinuation
- 2006-01-09 EP EP07023528A patent/EP1911756B9/en active Active
- 2006-01-09 US US11/327,896 patent/US20060155128A1/en not_active Abandoned
- 2006-01-09 GE GEAP200611119A patent/GEP20094828B/en unknown
- 2006-07-06 US US11/482,777 patent/US8362248B2/en active Active
- 2006-11-20 US US11/601,927 patent/US20070078150A1/en not_active Abandoned
-
2007
- 2007-02-16 HK HK07101889A patent/HK1094542A1/xx not_active IP Right Cessation
- 2007-07-02 IL IL184363A patent/IL184363A0/en unknown
- 2007-07-03 CR CR9225A patent/CR9225A/es not_active Application Discontinuation
- 2007-07-04 ZA ZA200705471A patent/ZA200705471B/en unknown
- 2007-07-04 NI NI200700169A patent/NI200700169A/es unknown
- 2007-07-20 NO NO20073806A patent/NO20073806L/no not_active Application Discontinuation
-
2008
- 2008-02-27 CY CY20081100225T patent/CY1107215T1/el unknown
- 2008-03-12 HR HR20080113T patent/HRP20080113T3/xx unknown
- 2008-07-10 HK HK08107588.5A patent/HK1112241A1/xx not_active IP Right Cessation
-
2009
- 2009-12-31 CY CY20091101355T patent/CY1109696T1/el unknown
-
2010
- 2010-01-07 HR HR20100008T patent/HRP20100008T1/hr unknown
- 2010-03-05 HN HN2010000430A patent/HN2010000430A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS51007B (sr) | Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga | |
| HRP20100614T1 (en) | 3,7-diamino-10h-phenothiazine salts and their use | |
| RS52978B (sr) | Fuzionisan amino piridin kao hsp90 inhibitori | |
| AR049739A1 (es) | Derivados de aril-piridina | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| ATE432272T1 (de) | Aminophenylderivate als neue inhibitoren von histondeacetylase | |
| WO2007016392A3 (en) | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | |
| EA200602058A1 (ru) | Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| MY150781A (en) | Phthalazine derivatives as parp inhibitors | |
| ECSP045064A (es) | Agonistas receptores de trombina | |
| RS53230B (sr) | Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora | |
| DK1836201T3 (da) | Pyrrolidininhibitorer af IAP | |
| UA85576C2 (ru) | Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата | |
| KR20050085991A (en) | Compounds exhibiting thrombopoietin receptor agonism | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| GEP20074148B (en) | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | |
| EA201000413A1 (ru) | Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида | |
| RS54708B1 (sr) | Ariletinil derivati | |
| AR049323A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de igf-1r y composiciones farmaceuticas que los componen. | |
| RS52881B (sr) | Benzamidinska jedinjenja koja su korisna kao inhibitori histonske deacetilaze | |
| TNSN06203A1 (en) | Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
| HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| TW200502225A (en) | Heterocyclic compounds useful as nurr-1 activators | |
| NO20064344L (no) | Caspaseinhibitorer og anvendelser derav |